Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing deep B-cell depletion and strong efficacy in early trials. Phase III is underway with robust funding, rapid community-based enrollment, and plans for broader autoimmune indications.Based on Artiva Biotherapeuti…
The conference highlighted a novel allogeneic NK cell therapy for refractory RA, showing strong efficacy and safety, with a pivotal phase III trial underway and broad expansion potential. Key milestones include updated clinical data, retreatment insights, and progress toward additional indications…